Japan EPA Lipid Intervention Study (JELIS). Randomized clinical trial involving primary and secondary prevention of cardiovascular events with EPA in hypercholesterolemia

Japanese Journal of Geriatrics

Volumn 46, Issue 1, 2009, Pages 22-25

  Yokoyama, Mitsuhiro ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ICOSAPENTAENOIC ACID;

ADULT; AGED; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; CORONARY DISEASE; EICOSAPENTAENOIC ACID; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED;

EID: 60549096876     PISSN: 03009173     EISSN: None     Source Type: Journal    
DOI: 10.3143/geriatrics.46.22     Document Type: Conference Paper

References (9)

1. He K, Song Y, Daviglus ML, Liu K, Horn LV, Dyer AR, et al.: Accumulated evidence on fish consumption and coronary heart disease mortality: a meta-analysis of cohort studies. Circulation 2004; 109: 2705-2711.
2. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Isikawa Y, et al.: Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients UELIS): a randomized open-label, blinded endpoint analysis. Lancet 2007; 369: 1090-1098.
3. Mozaffarian D: JELIS, fish oil, and cardiac events. Lancet 2007; 369: 1062-1063.
4. Yokoyama M, Origasa H, JELIS Investigators: Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). Am Heart J 2003; 146: 613-620.
5. Thies F, Garry JM, Yaqoob P, Perkasem K, Williams J, Shearman CP, et al.: Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 2003; 361: 477-485.
6. Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y, et al.: Effects of EPA on coronary artery disease in hypercholesterolemic patients with multple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2008; 200: 135-140.
7. Matsuzaki M, Yokoyama M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, et al.: Incremental effect of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease: A randomized controlled trial, (submitted).
8. Oikawa S, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, et al.: Incidence of coronary events and the suppressive effect of EPA in hypercholesteyolemic patients with impaired glucose metabolism: Sub-analysis of JELIS. (submitted).
9. Tanaka K, Ishikawa Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, et al.: Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients. Subanalysis of the JELIS trial. Stroke 2008; 39: 2052-2058.